Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Suspended 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 6Other hematologic neoplasm 4Lymphoid 4Breast 4Plasma cell 3Thoracic 2Head & Neck 2Tumor-Agnostic 1Other 1Myeloid 1Gynecologic 1

Conditions

Pneumonia 1Lung Neoplasms 1Lung Diseases, Interstitial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Clinical Protocols × Thoracic × Clear all
NCT04210492 2025-05-14

Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer

Yale University

Phase 1/2 Recruiting
36 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04036721 2023-02-23

PROS-CONS

National Institute for Tuberculosis and Lung Diseases, Poland

Phase 4 Suspended
85 enrolled
Thoracic

Lung Neoplasms, Pneumonia, Lung Diseases, Interstitial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡